Cepheid said this week that it has received clearance from the US Food and Drug Administration to market its Xpert C. difficile/Epi test.

Cepheid's first Xpert C. difficile test, which only detects C. difficile, has been available in the US since July 2009. The newly approved test additionally and simultaneously identifies the epidemic strain of C. difficile, also known as 027, NAP1, or BI, Cepheid said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.